Altimmune, Inc. — Form 8-K
Filed September 29, 2026 · analyzed by the 8-K Agent
8-K
— Neutral
significance 28/100
What the filing says
Form 8-K filed 2026-09-29 reports Item 5.02 (officer compensation) with period of report 2026-09-24. No specific dollar amounts, percentages, share counts, equity grants, salary changes, severance terms, or named officers are disclosed in the filing header or accessible summary. The actual compensation details are not provided in the text made available.
Why this rating
Routine officer compensation disclosure with no quantitative specifics. Cannot assess materiality without dollar amounts relative to ~$327M market cap. Standard periodic filing.
Extracted items
See more from September 29, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.